Developer docs
API playgroundTry for free, no card

Search company profiles

CHDI Foundation

Full company profile

uuid0009v3w

Namestring
CHDI Foundation
Legal namestring
CHDI Foundation, Inc.
Company typeenum
Private
Founded yearint
2002
Descriptiontext

CHDI Foundation is a privately-funded nonprofit biomedical research organization exclusively devoted to accelerating therapeutic development for Huntington's disease (HD). Founded circa 2002-2003 and headquartered in New York with additional offices in Los Angeles and Princeton, the foundation operates as a science management organization with approximately 200+ staff members working across these locations. CHDI employs a virtual operating model that funds and coordinates therapeutic development projects through collaborations with contract research organizations and a global network of more than 700 academic and industrial researchers. The foundation's mission is to de-risk therapeutic approaches in HD and advance them to a stage where pharmaceutical partners will invest in full clinical development.

CHDI's core platform assets are Enroll-HD, a worldwide HD clinical research platform and observational study launched in 2012 that has enrolled more than 28,000 participants across 155 clinical sites in 23 countries on four continents, and HDinHD, an open-science preclinical informatics portal. Additional resources include clinical biorepositories, HD mouse models, assays, antibodies, and other research tools that CHDI provides to the HD research community free of charge under a precompetitive sharing policy. The foundation typically does not assert intellectual property claims on reagents developed using its funding, and it organizes the annual HD Therapeutics Conference plus, in alternating years with the Huntington Study Group and European Huntington's Disease Network, the Huntington's Disease Clinical Research Conference.

CHDI's revenue model is private donor funding; the foundation has no commercial product revenue and provides its data, biosamples, and reagents without charge. Its customers are academic and industrial HD researchers, biotech and pharmaceutical partners (recently including Prilenia Therapeutics and Unlearn), 155 participating clinical research sites, and the broader HD patient and family community that participates in Enroll-HD. The foundation's scientific leadership spans dedicated VPs of Preclinical Biology, Chemistry, Fluid Biomarkers, Clinical Neuroimaging Research, Clinical Outcomes, and Program Management, supported by a C-suite including President Robi Blumenstein, CSO Robert Pacifici, COO Eileen Neacy, CMO Cristina Sampaio, and CLO David Rankin.

Short descriptiontext

CHDI Foundation is a privately-funded nonprofit biomedical research organization exclusively dedicated to accelerating therapeutic development for Huntington's disease, operating the Enroll-HD clinical platform (28,000+ participants, 23 countries) and providing open-access data, biosamples, and research tools to a global network of 700+ HD researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Huntington's disease research, clinical research platforms, biomedical research foundation, therapeutic development services, preclinical research resources
Industry3 codes
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
SECONDARYHLAJALAB
Health Research Funding Agencies (Public/Quasi-Public)
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Funding, Grants & Program Administration
NAICS code2 codes
  • Voluntary Health Organizations813212
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Health Services8000
Product category
Biomedical Research Foundation / Nonprofit Science Management
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Private Donor Funding
TypeData Monetisation
Description

CHDI Foundation is a privately-funded nonprofit biomedical research organization. As a nonprofit with no competitors in its disease focus, CHDI has no traditional revenue model - the organization is entirely funded through private donations and focuses its resources exclusively on Huntington's disease therapeutic development.

chdifoundation.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

CHDI Foundation is a privately-funded nonprofit biomedical research organization that exclusively accelerates therapeutic development for Huntington's disease. It operates the Enroll-HD worldwide clinical research platform (28,000+ participants across 155 sites in 23 countries), the HDinHD preclinical informatics portal, and provides mouse models, reagents, antibodies, clinical biosamples, and clinical infrastructure to the global HD research community free of charge. It also coordinates a network of more than 700 academic and industrial researchers and hosts the annual HD Therapeutics Conference to convene the field.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Enroll-HD platform supports faster and smarter clinical trial recruitment for HD therapeutic programs
+2 more records
Product overview1 text field

CHDI Foundation operates a science management organization focused exclusively on developing therapeutics for Huntington's disease. The organization provides a portfolio of interconnected resources including: Enroll-HD, a global clinical research platform with over 28,000 participants across 155 sites in 23 countries; HDinHD, a preclinical informatics platform for open science; and various research resources including clinical biorepositories, animal models, and research tools. CHDI also organizes the annual HD Therapeutics Conference and collaborates with academic HD researchers worldwide, acting as a collaborative enabler to lower barriers to entry for HD research.

Product and service7 records
1Enroll-HD
CategoryClinical research platform
Description

A worldwide Huntington's disease clinical research platform and observational study launched in 2012 that has enrolled more than 28,000 participants at 155 clinical sites in 23 countries across Europe, North America, Latin America, and Australasia. Enroll-HD supports clinical trial design, enables faster and smarter recruitment, makes all clinical data and biosamples collected available to the wider HD research community, and helps improve clinical care for HD.

2HDinHD (Preclinical Informatics)
CategoryPreclinical informatics platform
Description

An open science platform for Huntington's disease preclinical research that provides access to informatics tools, data sharing capabilities, and research resources for the HD scientific community.

3HD Therapeutics Conference
CategoryConference series
Description

An annual conference series focused on drug discovery and development for Huntington's disease, drawing participants and speakers from the biotech and pharmaceutical sectors as well as academia and research institutions. Serves as a forum for sharing ideas, learning about new disciplines, networking, and building collaborative partnerships.

4Clinical Biorepository
CategoryResearch resource
Description

A repository of clinical biosamples available to the Huntington's disease research community for biomarker discovery and validation studies.

5Mouse Models for HD Research
CategoryResearch resource
Description

Animal models for Huntington's disease research, including field guides and resources for researchers working with HD mouse models.

6Research Tools & Reagents
CategoryResearch resource
Description

Various research tools, reagents, and protocols made available to the HD research community to lower barriers to entry for working on Huntington's disease.

7Clinical Infrastructure & Capacity Building
CategorySupport service
Description

Building clinical infrastructure and capacity so that as soon as promising therapeutics are ready, the wider HD research community can quickly progress to clinical trials.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-26
Description

Prilenia Therapeutics announced a Data Use Agreement with CHDI Foundation to provide clinical data from the placebo arms of its PRIDE and PROOF studies for Huntington's disease research. CHDI receives a worldwide, non-exclusive license to use individual patient-level data and can share it with qualified third-party research institutions. The collaboration aims to improve clinical trial design and support the development of more effective treatments for Huntington's disease.

2Unlearn
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-24
Description

Unlearn, an AI company specializing in clinical development, is refining its Huntington's disease-specific Digital Twin Generator by training it with longitudinal patient data from CHDI Foundation's Enroll-HD clinical research platform. The platform contains data from over 22,000 active participants across 157 sites in 23 countries. The AI-generated digital twins are used in clinical trials to reduce variability and support treatment effect estimation, with the collaboration intended to accelerate progress for the Huntington's disease community.

morningstar.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CHDI works with the Huntington Study Group (HSG) to co-organize the Huntington's Disease Clinical Research Conference, held alternately in the US and Europe. HSG is a major clinical research organization dedicated to Huntington's disease.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CHDI collaborates with EHDN to co-organize the Huntington's Disease Clinical Research Conference, held alternately in the US and Europe. EHDN is a European network dedicated to Huntington's disease research and clinical care.

5HD Advocacy Organizations Worldwide
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CHDI works closely with HD advocacy organizations worldwide including HDSA (Huntington's Disease Society of America), Huntington Society of Canada, and others to forge links between HD families and researchers/clinicians to speed the drug development process.

chdifoundation.org
6HDYO (Huntington's Disease Youth Organization)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

CHDI supports and participates in HDYO Congress events, which bring together young people affected by Huntington's disease for education and networking.

chdifoundation.org
7Academic Research Institutions (Global Network of 700+ Researchers)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

CHDI funds and collaborates with academic HD researchers around the world, with science directors and project managers working closely with a network of more than 700 researchers in academic and industrial laboratories globally. CHDI staff scientists manage internal therapeutic programs through collaborations at contract research organizations.

chdifoundation.org
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

A major nonprofit foundation that funds cystic fibrosis research and operates a similar venture philanthropy model — investing in therapeutic development and clinical infrastructure to accelerate drug discovery. Comparable to CHDI as a disease-focused biomedical research foundation with patient data infrastructure and major pharma partnerships.

TypeDirect peer
Description

A nonprofit that funds neuromuscular disease research, operates clinical care infrastructure, and partners with biotech/pharma companies. Comparable to CHDI in mission model, scale, and use of donor funding to advance therapeutic development for a specific disease area.

3Alzheimer's Association
TypeBroad incumbent
Description

The largest nonprofit funder of Alzheimer's research, operating clinical data initiatives and pharmaceutical partnerships to accelerate therapeutic development. Comparable to CHDI as a CNS-focused research foundation with data infrastructure and significant pharma engagement.

TypeDirect peer
Description

A leading ALS-focused nonprofit that funds research, operates clinical infrastructure, and partners with biotech/pharma to accelerate therapeutic development. Comparable to CHDI as a disease-focused research foundation with clinical data platforms and a portfolio approach to therapeutic funding.

TypeDirect peer
Description

The original foundation that funded the discovery of the Huntington's disease gene and provided the lineage from which CHDI Foundation emerged. Directly comparable as a nonprofit focused exclusively on hereditary disease research with a long-standing role in HD therapeutic advancement.

6Friedreich's Ataxia Research Alliance (FARA)
TypeDirect peer
Description

A rare disease nonprofit focused on Friedreich's ataxia that operates a similar collaborative model — funding research, supporting clinical infrastructure, and partnering with biotech to advance therapeutics. Comparable to CHDI as a smaller-scale, rare-disease research foundation.

TypeDirect peer
Description

A nonprofit that drives Parkinson's disease therapeutic development through research funding, clinical data platforms (similar to Enroll-HD), and partnerships with pharma/biotech. Highly comparable to CHDI in operating model, neuroscience focus, and use of precompetitive data sharing to accelerate CNS drug discovery.

TypeDirect peer
Description

A clinical research organization exclusively focused on Huntington's disease that conducts clinical trials and observational studies. Directly comparable as a core HD clinical research partner — CHDI co-organizes conferences with HSG and collaborates on HD clinical infrastructure.

TypeBroad incumbent
Description

One of the largest disease-focused nonprofits, funding blood cancer research through grants, clinical trials, and biotech partnerships. Comparable to CHDI in scale, donor funding model, and role in advancing therapeutic development across a specific disease portfolio.

TypeBroad incumbent
Description

A major nonprofit funding MS research through grants, clinical infrastructure, and pharma partnerships. Comparable to CHDI as a CNS-focused research foundation with established clinical platforms and a multi-decade operating history.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat7 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles21 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CHDI Foundation

Biomedical Research Foundation / Nonprofit Science Managementchdifoundation.org

CHDI Foundation is a privately-funded nonprofit biomedical research organization exclusively dedicated to accelerating therapeutic development for Huntington's disease, operating the Enroll-HD clinical platform (28,000+ participants, 23 countries) and providing open-access data, biosamples, and research tools to a global network of 700+ HD researchers.

What CHDI Foundation does

CHDI Foundation is a privately-funded nonprofit biomedical research organization exclusively devoted to accelerating therapeutic development for Huntington's disease (HD). Founded circa 2002-2003 and headquartered in New York with additional offices in Los Angeles and Princeton, the foundation operates as a science management organization with approximately 200+ staff members working across these locations. CHDI employs a virtual operating model that funds and coordinates therapeutic development projects through collaborations with contract research organizations and a global network of more than 700 academic and industrial researchers. The foundation's mission is to de-risk therapeutic approaches in HD and advance them to a stage where pharmaceutical partners will invest in full clinical development.

CHDI's core platform assets are Enroll-HD, a worldwide HD clinical research platform and observational study launched in 2012 that has enrolled more than 28,000 participants across 155 clinical sites in 23 countries on four continents, and HDinHD, an open-science preclinical informatics portal. Additional resources include clinical biorepositories, HD mouse models, assays, antibodies, and other research tools that CHDI provides to the HD research community free of charge under a precompetitive sharing policy. The foundation typically does not assert intellectual property claims on reagents developed using its funding, and it organizes the annual HD Therapeutics Conference plus, in alternating years with the Huntington Study Group and European Huntington's Disease Network, the Huntington's Disease Clinical Research Conference.

CHDI's revenue model is private donor funding; the foundation has no commercial product revenue and provides its data, biosamples, and reagents without charge. Its customers are academic and industrial HD researchers, biotech and pharmaceutical partners (recently including Prilenia Therapeutics and Unlearn), 155 participating clinical research sites, and the broader HD patient and family community that participates in Enroll-HD. The foundation's scientific leadership spans dedicated VPs of Preclinical Biology, Chemistry, Fluid Biomarkers, Clinical Neuroimaging Research, Clinical Outcomes, and Program Management, supported by a C-suite including President Robi Blumenstein, CSO Robert Pacifici, COO Eileen Neacy, CMO Cristina Sampaio, and CLO David Rankin.

CHDI Foundation firmographics

Firmographics
Name
CHDI Foundation
Legal name
CHDI Foundation, Inc.
Website
https://chdifoundation.org
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
101–250 employees
Short description
CHDI Foundation is a privately-funded nonprofit biomedical research organization exclusively dedicated to accelerating therapeutic development for Huntington's disease, operating the Enroll-HD clinical platform (28,000+ participants, 23 countries) and providing open-access data, biosamples, and research tools to a global network of 700+ HD researchers.
Ownership category
akta.pro rank

CHDI Foundation industry classification

Industry
Product category
Biomedical Research Foundation / Nonprofit Science Management
NAICS
Voluntary Health Organizations (813212), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Health Services (8000)
akta.pro industry
PRIMARYBPAGACAA
Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS)
SECONDARYHLAJAOAM
Global Health Research, Clinical Trials & Product Development Partnerships (PDPs)
SECONDARYHLAJALAB
Health Research Funding Agencies (Public/Quasi-Public)
Healthcare & Life Sciences/Public Health, Government & Regulators/Public Health Funding, Grants & Program Administration

Keywords

  • Huntington's disease research
  • Clinical research platforms
  • Biomedical research foundation
  • Therapeutic development services
  • Preclinical research resources

Where CHDI Foundation is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices3 records

Markets served

CHDI Foundation business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Private Donor Funding: CHDI Foundation is a privately-funded nonprofit biomedical research organization. As a nonprofit with no competitors in its disease focus, CHDI has no traditional revenue model - the organization is entirely funded through private donations and focuses its resources exclusively on Huntington's disease therapeutic development.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

CHDI Foundation product offering

Product offering

Core offering

CHDI Foundation is a privately-funded nonprofit biomedical research organization that exclusively accelerates therapeutic development for Huntington's disease. It operates the Enroll-HD worldwide clinical research platform (28,000+ participants across 155 sites in 23 countries), the HDinHD preclinical informatics portal, and provides mouse models, reagents, antibodies, clinical biosamples, and clinical infrastructure to the global HD research community free of charge. It also coordinates a network of more than 700 academic and industrial researchers and hosts the annual HD Therapeutics Conference to convene the field.

Product overview

CHDI Foundation operates a science management organization focused exclusively on developing therapeutics for Huntington's disease. The organization provides a portfolio of interconnected resources including: Enroll-HD, a global clinical research platform with over 28,000 participants across 155 sites in 23 countries; HDinHD, a preclinical informatics platform for open science; and various research resources including clinical biorepositories, animal models, and research tools. CHDI also organizes the annual HD Therapeutics Conference and collaborates with academic HD researchers worldwide, acting as a collaborative enabler to lower barriers to entry for HD research.

Differentiator

Problem solved

Functional benefit

Products and services

  • Enroll-HD A worldwide Huntington's disease clinical research platform and observational study launched in 2012 that has enrolled more than 28,000 participants at 155 clinical sites in 23 countries across Europe, North America, Latin America, and Australasia. Enroll-HD supports clinical trial design, enables faster and smarter recruitment, makes all clinical data and biosamples collected available to the wider HD research community, and helps improve clinical care for HD.
  • HDinHD (Preclinical Informatics) An open science platform for Huntington's disease preclinical research that provides access to informatics tools, data sharing capabilities, and research resources for the HD scientific community.
  • HD Therapeutics Conference An annual conference series focused on drug discovery and development for Huntington's disease, drawing participants and speakers from the biotech and pharmaceutical sectors as well as academia and research institutions. Serves as a forum for sharing ideas, learning about new disciplines, networking, and building collaborative partnerships.
  • Clinical Biorepository A repository of clinical biosamples available to the Huntington's disease research community for biomarker discovery and validation studies.
  • Mouse Models for HD Research Animal models for Huntington's disease research, including field guides and resources for researchers working with HD mouse models.
  • Research Tools & Reagents Various research tools, reagents, and protocols made available to the HD research community to lower barriers to entry for working on Huntington's disease.
  • Clinical Infrastructure & Capacity Building Building clinical infrastructure and capacity so that as soon as promising therapeutics are ready, the wider HD research community can quickly progress to clinical trials.

Quantifiable outcome

  • Enroll-HD platform supports faster and smarter clinical trial recruitment for HD therapeutic programs
  • +2 more outcomes

Companies that use CHDI Foundation

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles3 records

CHDI Foundation technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

CHDI Foundation partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Prilenia TherapeuticscoreStrategic or Co-development Partner · 26 May 2026Prilenia Therapeutics announced a Data Use Agreement with CHDI Foundation to provide clinical data from the placebo arms of its PRIDE and PROOF studies for Huntington's disease research. CHDI receives a worldwide, non-exclusive license to use individual patient-level data and can share it with qualified third-party research institutions. The collaboration aims to improve clinical trial design and support the development of more effective treatments for Huntington's disease.
  • UnlearncoreStrategic or Co-development Partner · 24 February 2026Unlearn, an AI company specializing in clinical development, is refining its Huntington's disease-specific Digital Twin Generator by training it with longitudinal patient data from CHDI Foundation's Enroll-HD clinical research platform. The platform contains data from over 22,000 active participants across 157 sites in 23 countries. The AI-generated digital twins are used in clinical trials to reduce variability and support treatment effect estimation, with the collaboration intended to accelerate progress for the Huntington's disease community.
  • Huntington Study GroupcoreStrategic or Co-development PartnerCHDI works with the Huntington Study Group (HSG) to co-organize the Huntington's Disease Clinical Research Conference, held alternately in the US and Europe. HSG is a major clinical research organization dedicated to Huntington's disease.
  • European Huntington's Disease Network (EHDN)coreStrategic or Co-development PartnerCHDI collaborates with EHDN to co-organize the Huntington's Disease Clinical Research Conference, held alternately in the US and Europe. EHDN is a European network dedicated to Huntington's disease research and clinical care.
  • HD Advocacy Organizations WorldwidecoreStrategic or Co-development PartnerCHDI works closely with HD advocacy organizations worldwide including HDSA (Huntington's Disease Society of America), Huntington Society of Canada, and others to forge links between HD families and researchers/clinicians to speed the drug development process.
  • HDYO (Huntington's Disease Youth Organization)minorStrategic or Co-development PartnerCHDI supports and participates in HDYO Congress events, which bring together young people affected by Huntington's disease for education and networking.
  • Academic Research Institutions (Global Network of 700+ Researchers)coreStrategic or Co-development PartnerCHDI funds and collaborates with academic HD researchers around the world, with science directors and project managers working closely with a network of more than 700 researchers in academic and industrial laboratories globally. CHDI staff scientists manage internal therapeutic programs through collaborations at contract research organizations.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

CHDI Foundation competitors and assessment

Company assessment

Broad incumbents

  • Cystic Fibrosis Foundation: A major nonprofit foundation that funds cystic fibrosis research and operates a similar venture philanthropy model — investing in therapeutic development and clinical infrastructure to accelerate drug discovery. Comparable to CHDI as a disease-focused biomedical research foundation with patient data infrastructure and major pharma partnerships.
  • Alzheimer's Association: The largest nonprofit funder of Alzheimer's research, operating clinical data initiatives and pharmaceutical partnerships to accelerate therapeutic development. Comparable to CHDI as a CNS-focused research foundation with data infrastructure and significant pharma engagement.
  • Leukemia & Lymphoma Society: One of the largest disease-focused nonprofits, funding blood cancer research through grants, clinical trials, and biotech partnerships. Comparable to CHDI in scale, donor funding model, and role in advancing therapeutic development across a specific disease portfolio.
  • National Multiple Sclerosis Society: A major nonprofit funding MS research through grants, clinical infrastructure, and pharma partnerships. Comparable to CHDI as a CNS-focused research foundation with established clinical platforms and a multi-decade operating history.

Direct peers

  • Muscular Dystrophy Association: A nonprofit that funds neuromuscular disease research, operates clinical care infrastructure, and partners with biotech/pharma companies. Comparable to CHDI in mission model, scale, and use of donor funding to advance therapeutic development for a specific disease area.
  • ALS Association: A leading ALS-focused nonprofit that funds research, operates clinical infrastructure, and partners with biotech/pharma to accelerate therapeutic development. Comparable to CHDI as a disease-focused research foundation with clinical data platforms and a portfolio approach to therapeutic funding.
  • Hereditary Disease Foundation: The original foundation that funded the discovery of the Huntington's disease gene and provided the lineage from which CHDI Foundation emerged. Directly comparable as a nonprofit focused exclusively on hereditary disease research with a long-standing role in HD therapeutic advancement.
  • Friedreich's Ataxia Research Alliance (FARA): A rare disease nonprofit focused on Friedreich's ataxia that operates a similar collaborative model — funding research, supporting clinical infrastructure, and partnering with biotech to advance therapeutics. Comparable to CHDI as a smaller-scale, rare-disease research foundation.
  • Michael J. Fox Foundation for Parkinson's Research: A nonprofit that drives Parkinson's disease therapeutic development through research funding, clinical data platforms (similar to Enroll-HD), and partnerships with pharma/biotech. Highly comparable to CHDI in operating model, neuroscience focus, and use of precompetitive data sharing to accelerate CNS drug discovery.
  • Huntington Study Group: A clinical research organization exclusively focused on Huntington's disease that conducts clinical trials and observational studies. Directly comparable as a core HD clinical research partner — CHDI co-organizes conferences with HSG and collaborates on HD clinical infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat7 records

Key risks5 records

Key highlights7 records

Customer concentration

CHDI Foundation financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CHDI Foundation leadership team

Management profile

Number of profiles

Profiles21 records

CHDI Foundation funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CHDI Foundation M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CHDI Foundation

What does CHDI Foundation do?

CHDI Foundation is a privately-funded nonprofit biomedical research organization that exclusively accelerates therapeutic development for Huntington's disease. It operates the Enroll-HD worldwide clinical research platform (28,000+ participants across 155 sites in 23 countries), the HDinHD preclinical informatics portal, and provides mouse models, reagents, antibodies, clinical biosamples, and clinical infrastructure to the global HD research community free of charge. It also coordinates a network of more than 700 academic and industrial researchers and hosts the annual HD Therapeutics Conference to convene the field.

Is CHDI Foundation a public or private company?

CHDI Foundation is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was CHDI Foundation founded?

CHDI Foundation was founded in 2002. It employs 101 to 250 people.

Where is CHDI Foundation based?

CHDI Foundation is headquartered in New York, United States, in the North America region.

How does CHDI Foundation make money?

One revenue line is on record: private Donor Funding.

Who are CHDI Foundation's main competitors?

Broad incumbents on record are Cystic Fibrosis Foundation, Alzheimer's Association, Leukemia & Lymphoma Society and National Multiple Sclerosis Society. Direct peers are Muscular Dystrophy Association, ALS Association, Hereditary Disease Foundation, Friedreich's Ataxia Research Alliance (FARA), Michael J. Fox Foundation for Parkinson's Research and Huntington Study Group.

Does CHDI Foundation have an API?

No public API is recorded for CHDI Foundation.

What industry is CHDI Foundation in?

CHDI Foundation's product category is Biomedical Research Foundation / Nonprofit Science Management. Its primary akta.pro industry code is BPAGACAA, Disease-Specific Research & Support (e.g., Cancer, Diabetes, ALS), with a secondary code of HLAJAOAM, Global Health Research, Clinical Trials & Product Development Partnerships (PDPs). Its NAICS code is 813212 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogPrilenia Donates Clinical Trial Datasets to CHDI Foundation to Advance Huntington's Disease ResearchPrilenia Therapeutics announced a Data Use Agreement with CHDI Foundation to provide clinical data from the placebo arms of its PRIDE and PROOF studies for Huntington's disease research. Under the agreement, CHDI receives a worldwide, non-exclusive license to use individual patient-level data and can share it with qualified third-party research institutions. The collaboration aims to improve clinical trial design and support the development of more effective treatments for Huntington's disease.MorningstarUnlearn Advances Huntington's Disease AI Modeling Through Access to CHDI Foundation DataUnlearn, an AI company specializing in clinical development, announced it will refine its Huntington's disease-specific Digital Twin Generator by training it with longitudinal patient data from CHDI Foundation's Enroll-HD clinical research platform. The Enroll-HD platform contains data from over 22,000 active participants across 157 sites in 23 countries, providing high-quality data essential for advancing disease-specific modeling in neurodegenerative disorders. The AI-generated digital twins are used in clinical trials to reduce variability and support treatment effect estimation, with the collaboration intended to accelerate progress for the Huntington's disease community.PR NewswireMolecular Design Platform Accelerating Research For Huntington's DiseaseOpenEye Scientific and CHDI Foundation announced a research collaboration to identify novel small-molecule therapeutics for Huntington's disease using Orion, OpenEye's cloud-native molecular design platform. The collaboration will search 475 billion enumerated 3D structures (representing 2.5 billion compounds) to identify molecules that bind the huntingtin protein, with searches completed in under 24 hours using AWS cloud computing. There are currently no approved therapeutics that slow Huntington's disease progression, which affects approximately one in 10,000 people worldwide.GlobeNewswireWave Life Sciences to Present Preclinical In Vivo and In Vitro Data for SNP3-Targeting Huntington’s Disease Program at CHDI Foundation’s 15th Annual HD Therapeutics ConferenceWave Life Sciences will present preclinical in vivo and in vitro data for its SNP3-targeting Huntington's disease program at the CHDI Foundation's 15th Annual HD Therapeutics Conference in Palm Springs, February 24-27, 2020. The poster covers stereopure oligonucleotides designed to selectively silence mutant huntingtin mRNA. Wave expects to initiate clinical development of a SNP3-targeting candidate in the second half of 2020.PR NewswirePotential Treatment for Huntington's Disease, Found Effective, Safe in Mice, Monkeys, Enters Clinical TestingA drug called IONIS-HTTRx, developed by Ionis Pharmaceuticals in collaboration with CHDI Foundation and Roche Pharmaceuticals, has demonstrated effectiveness and safety in mouse and monkey models of Huntington's disease, with up to 50 percent reduction in cortical huntingtin levels achieved in monkeys. The antisense drug, which acts as a gene silencer to inhibit production of the disease-causing huntingtin protein, has now entered a Phase 1/2a clinical study in humans with four monthly doses to evaluate safety, tolerability, and pharmacokinetics. If successful, it would be the first treatment to target the underlying cause of Huntington's disease rather than just managing symptoms.GlobeNewswireSingulex Announces Collaboration With CHDI Foundation to Develop Biomarker Assays for Huntington's DiseaseSingulex and CHDI Foundation announced a collaboration to develop Huntington's disease biomarkers using Singulex's Erenna immunoassay. The assay detects mutant huntingtin protein in cerebrospinal fluid, with levels higher in advanced disease and predicting symptom severity. The partnership aims to support trials of huntingtin-lowering therapeutics.GlobeNewswireGalapagos and CHDI Foundation, Inc. enter new five-year collaboration for Huntington's disease therapeuticsGalapagos and CHDI Foundation announced a new five-year collaboration to discover Huntington's disease therapeutics, with BioFocus eligible for $41 million in research fees. The agreement expands the partnership started in 2005, continuing their work on novel drugs for the disease.GlobeNewswireEvotec and CHDI Foundation, Inc. Extend Collaboration to Fight Huntington's DiseaseEvotec extended its collaboration with CHDI Foundation to end of 2012 to accelerate Huntington's disease drug development. The alliance provides up to $37.5 million in research funding over three years. Evotec will provide integrated drug discovery services, including screening and target validation.